(Q34422252)

2 August 2017

title

Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer (English)

1 reference

2 August 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882381%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Daniel D Von Hoff

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882381%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

publication date

31 May 2014

1 reference

Expert Review of Gastroenterology & Hepatology

2 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882381%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882381%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882381%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

739-747

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882381%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Advanced pancreatic carcinoma: current treatment and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Combinational therapy: new hope for pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

nab-Paclitaxel mechanisms of action and delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

The winning formulation: the development of paclitaxel in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Familial pancreatic cancer: genetic advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

Cracking the stone: combination vaccination and CTLA-4 blockade in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.925799

10.1586/17474124.2014.925799

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882381%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1 reference